The patient, diagnosed with Luminal B (HER2 positive) breast cancer, showed progress after anti-HER2 neoadjuvant treatment (including trastuzumab) according to the Response Evaluation Criteria in Solid Tumors version 1.1 guidelines (Fig. 1a). Here, ERBB2 is linked to breast carcinoma.